Yuichi Iwaki
President and CEO
Delivering innovation where it matters most.
We are continuing to progress our pipeline designed to create meaningful value in areas of medicine where the unmet need is substantial and the market opportunity is significant. Our strategy is focused, datadriven, and built to deliver sustainable growth as a global biopharmaceutical company listed on NASDAQ and the Tokyo Stock Exchange.
We operate in therapeutic areas defined by scientific complexity and limited competition—spaces where differentiated science can reshape standards of care and unlock longterm value. By targeting indications with high unmet medical need and attractive market dynamics, we position our pipeline to generate impact for patients and compelling returns for investors.
Execution is our priority. We advance programs with clear scientific rationale, accelerate development along the most efficient regulatory pathways, and leverage global partnerships to expand reach and reduce development risk. This disciplined approach enables us to deploy capital efficiently while maintaining the agility required in today’s dynamic biotech environment.
Patients remain the center of everything we do. Their urgency drives our pace; their resilience reinforces our commitment to scientific excellence, operational precision, and transparent value creation. As we progress, we remain focused on building a pipeline capable of driving both clinical impact and longterm shareholder value.